Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Roussou

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 24, 2020
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implicationsPanagiotis Kokotis, Efstathios Manios, Martin Schmelz, et al.
Haematologica|May 10, 2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agentsEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
American Journal of Hematology|June 13, 2013
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimensTina Bagratuni, Efstathios Kastritis, Marianna Politou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patientsEvangelos Terpos, Anna Tasidou, Evangelos Eleftherakis-Papaiakovou, et al.
Leukemia & Lymphoma|June 13, 2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapyEfstathios Kastritis, Pelagia Melea, Tina Bagratuni, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2011
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myelomaMaria Gkotzamanidou, Efstathios Kastritis, Maria Roussou Magdalini Migkou Maria Gavriatopoulou, et al.
European Journal of Haematology|June 3, 2011
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapyMagdalini Migkou, Efstathios Kastritis, Maria Roussou, et al.
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 25, 2018
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström MacroglobulinemiaEvangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, et al.
European Journal of Haematology|March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairmentMeletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 24, 2020
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implicationsPanagiotis Kokotis, Efstathios Manios, Martin Schmelz, et al.
Haematologica|May 10, 2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agentsEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
American Journal of Hematology|June 13, 2013
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimensTina Bagratuni, Efstathios Kastritis, Marianna Politou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patientsEvangelos Terpos, Anna Tasidou, Evangelos Eleftherakis-Papaiakovou, et al.
Leukemia & Lymphoma|June 13, 2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapyEfstathios Kastritis, Pelagia Melea, Tina Bagratuni, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2011
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myelomaMaria Gkotzamanidou, Efstathios Kastritis, Maria Roussou Magdalini Migkou Maria Gavriatopoulou, et al.
European Journal of Haematology|June 3, 2011
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapyMagdalini Migkou, Efstathios Kastritis, Maria Roussou, et al.
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 25, 2018
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström MacroglobulinemiaEvangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, et al.
European Journal of Haematology|March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairmentMeletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Pageof 8